(firstQuint)Combined Treatment of Sorafenib and Pegylated Interferon 2b in Stage IV Metastatic Melanoma.

 This is a a prospective non-randomized, multicenter Phase II Study to evaluate the efficacy and safety of a combined treatment with Sorafenib (Nexavar(R)) and pegylated interferon--2b (PegIntron(R)) in patients with malignant melanoma in stage IV.

 The investigators will determine disease control rate (CR,PR,SD) after 8 weeks of treatment with pegylated interferon- -2b (3 mu g/kg body weight s.

c.

 once a week) combined with Sorafenib 2x 400 mg (2 tablets orally, twice daily).

 Combined Treatment of Sorafenib and Pegylated Interferon 2b in Stage IV Metastatic Melanoma@highlight

To evaluate the efficacy and safety of a combined treatment with Sorafenib (Nexavar(R)) and pegylated interferon--2b (PegIntron(R)) in patients with malignant melanoma in stage IV.

